Many people have diabetes but don’t know it. During the month of March the American Red Cross will be helping to bridge access to health care by providing a free A1C (diabetes screening) test for ...

Screening for the second leading cause of cancer deaths just got a bit easier. The U.S. Food and Drug Administration (FDA) announced the approval of a new blood test for colorectal cancer (CRC).

CLEVELAND, Ohio — The American Red Cross of Northern Ohio in March is providing blood donors free A1C testing, commonly used to screen for diabetes and pre-diabetes, and a $10 Amazon.com gift card, ...

In July, the US Food and Drug Administration (FDA) approved a new blood-based test to screen for colorectal cancer (CRC). The FDA's approval of Shield (Guardant Health) marks a notable achievement, as ...

Testing a person’s blood for a type of protein called phosphorylated tau, or p-tau, could be used to screen for Alzheimer’s disease with “high accuracy,” even before symptoms begin to show, a new ...

A groundbreaking blood test for colorectal cancer screening has received approval from the U.S. Food and Drug Administration (FDA), offering the potential to revolutionize early detection for one of ...

The US Food and Drug Administration has approved a blood test to be used for colorectal cancer screening among average-risk adults 45 and older. The maker of the test, Palo Alto, California-based ...

50 million Americans due for colon cancer screening avoid it because they consider traditional tests so unpleasant. But now it can be as simple as a blood test. If you’re overdue for your colon cancer ...

The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn't meant to replace colonoscopies, but is generating enthusiasm ...

The test's maker said the FDA will likely decide on approval later this year. A blood test to screen for colorectal cancer is one step closer to receiving approval from the U.S. Food and Drug ...

OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch ® 3D genomics platform, today ...